Browse ASB4

Summary
SymbolASB4
Nameankyrin repeat and SOCS box containing 4
Aliases ASB-4; ankyrin repeat and SOCS box-containing 4; Ankyrin repeat and SOCS box protein 4
Chromosomal Location7q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF12796 Ankyrin repeats (3 copies)
PF07525 SOCS box
Function

Probable substrate-recognition component of a SCF-like ECS (Elongin-Cullin-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Promotes differentiation and maturation of the vascular lineage by an oxygen-dependent mechanism (By similarity).

> Gene Ontology
 
Biological Process GO:0001570 vasculogenesis
GO:0048514 blood vessel morphogenesis
GO:0051865 protein autoubiquitination
GO:1901342 regulation of vasculature development
GO:1904018 positive regulation of vasculature development
GO:2001212 regulation of vasculogenesis
GO:2001214 positive regulation of vasculogenesis
Molecular Function GO:0004842 ubiquitin-protein transferase activity
GO:0019787 ubiquitin-like protein transferase activity
GO:0031625 ubiquitin protein ligase binding
GO:0044389 ubiquitin-like protein ligase binding
GO:0061630 ubiquitin protein ligase activity
GO:0061659 ubiquitin-like protein ligase activity
Cellular Component GO:0000151 ubiquitin ligase complex
GO:0031461 cullin-RING ubiquitin ligase complex
GO:0031462 Cul2-RING ubiquitin ligase complex
GO:0031466 Cul5-RING ubiquitin ligase complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-983168: Antigen processing
R-HSA-983169: Class I MHC mediated antigen processing & presentation
R-HSA-168256: Immune System
Summary
SymbolASB4
Nameankyrin repeat and SOCS box containing 4
Aliases ASB-4; ankyrin repeat and SOCS box-containing 4; Ankyrin repeat and SOCS box protein 4
Chromosomal Location7q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ASB4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ASB4 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29371260Colorectal carcinomaPromote immunity (T cell function); essential for immunotherapyThe Antigen ASB4 on Cancer Stem Cells Serves as a Target for CTL Immunotherapy of Colorectal Cancer. Therefore, ASB4 is a tumor-associated antigen that can elicit CTL responses specific to CSCs and can discriminate between two cellular subsets of colorectal cancer.
Summary
SymbolASB4
Nameankyrin repeat and SOCS box containing 4
Aliases ASB-4; ankyrin repeat and SOCS box-containing 4; Ankyrin repeat and SOCS box protein 4
Chromosomal Location7q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ASB4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolASB4
Nameankyrin repeat and SOCS box containing 4
Aliases ASB-4; ankyrin repeat and SOCS box-containing 4; Ankyrin repeat and SOCS box protein 4
Chromosomal Location7q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ASB4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.6970.24
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1210.901
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.110.176
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2680.666
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.890.392
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5190.669
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.5040.607
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3640.784
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2280.88
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.5470.611
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.5590.69
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2850.252
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ASB4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.516.7-4.21
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolASB4
Nameankyrin repeat and SOCS box containing 4
Aliases ASB-4; ankyrin repeat and SOCS box-containing 4; Ankyrin repeat and SOCS box protein 4
Chromosomal Location7q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ASB4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolASB4
Nameankyrin repeat and SOCS box containing 4
Aliases ASB-4; ankyrin repeat and SOCS box-containing 4; Ankyrin repeat and SOCS box protein 4
Chromosomal Location7q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ASB4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ASB4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolASB4
Nameankyrin repeat and SOCS box containing 4
Aliases ASB-4; ankyrin repeat and SOCS box-containing 4; Ankyrin repeat and SOCS box protein 4
Chromosomal Location7q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ASB4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolASB4
Nameankyrin repeat and SOCS box containing 4
Aliases ASB-4; ankyrin repeat and SOCS box-containing 4; Ankyrin repeat and SOCS box protein 4
Chromosomal Location7q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ASB4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolASB4
Nameankyrin repeat and SOCS box containing 4
Aliases ASB-4; ankyrin repeat and SOCS box-containing 4; Ankyrin repeat and SOCS box protein 4
Chromosomal Location7q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ASB4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolASB4
Nameankyrin repeat and SOCS box containing 4
Aliases ASB-4; ankyrin repeat and SOCS box-containing 4; Ankyrin repeat and SOCS box protein 4
Chromosomal Location7q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ASB4 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.